胃癌中MET的表达及与克唑替尼敏感性的关系

目的:研究间质表皮转化生长因子受体(MET)的表达与胃癌患者的临床病理特征、生存期、靶向药物克唑替尼的敏感性的关系。方法:采用免疫组化法（IHC）检测118例经手术切除的胃癌组织MET的表达，通过三维微组织块培养法（HDRA）进行克唑替尼的体外敏感性实验。结果:35.6%的胃癌患者高表达MET。MET的表达与年龄（P=0.442）、性别（P=0.237）、肿瘤部位（P=0.101）、疾病分期（P=0.229）及组织学分级（P=0.811）无关，与Lauren分型有显著相关性（P=0.000）。MET表达水平与克唑替尼的敏感性呈正相关（P=0.009）。MET高表达者和低表达者的总生存期分别为17.3月和18.1月，两者无显著性差异（P=0.989）。结论:MET表达水平与胃癌的Lauren分型相型相关，也是预测胃癌组织对克唑替尼敏感性的潜在指标。

Correlation of MET expression and crizotinib sensitivity in gastric cancer

Objective:To investigate the correlation between MET overexpression with clinical pathological characteristics,crizotinib response and survival time in the gastric cancer patients.Methods:The MET expression of 118 gastric carcinoma patients was explored using immunohistochemical(IHC).The correlation of MET expression with clinic pathological features and survival time were analyzed.In vitro crizotinib sensitivity was studied by histoculture drug response assay.Results:The positive rate of MET in gastric cancer patients was 35.6%.There was no significant correlation between MET and clinical characteristics,including age(P=0.442),gender(P=0.237),tumor site(P=0.101),stage(P=0.229),or histological grade(P=0.811).The MET expression was correlated with lauren classification(P=0.000)and sensitivity to crizotinib(P=0.009)．No significant OS difference was observed between MET-high and MET-low cohorts(17.3 months vs 18.1 months,P=0.989).Conclusion:MET overexpression is closely associated with lauren classification and may forecast crizotinib anticancer effect in gastric cancer patients.